Trial Profile
A Single-Dose, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen Idec
- 17 Nov 2011 Actual initiation date changed from Nov 2010 to Oct 2010 as reported by ClinicalTrials.gov.
- 13 Jan 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 13 Jan 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.